Filing Details

Accession Number:
0001439222-21-000059
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-22 16:44:19
Reporting Period:
2021-06-18
Accepted Time:
2021-06-22 16:44:19
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1439222 Agios Pharmaceuticals Inc. AGIO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1608601 Christopher Bowden C/O Agios Pharmaceuticals, Inc.
88 Sidney Street
Cambridge MA 02139
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-18 1,885 $39.76 17,372 No 4 M Direct
Common Stock Acquisiton 2021-06-18 46,608 $50.40 63,980 No 4 M Direct
Common Stock Disposition 2021-06-18 48,493 $60.11 15,487 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2021-06-18 1,885 $0.00 1,885 $39.76
Common Stock Stock option (right to buy) Disposition 2021-06-18 46,608 $0.00 46,608 $50.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2026-02-15 No 4 M Direct
992 2027-02-20 No 4 M Direct
Footnotes
  1. This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  3. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.31. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
  4. This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter.
  5. This option was granted on February 21, 2017. The shares underlying this option vest as to 25% of the underlying shares on February 21, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.